bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today announced the pricing of an underwritten public offering of 2,650,000 shares of its common stock at a public offering price of $85.00 per share, before underwriting discounts. In addition, bluebird bio has granted the underwriters a 30-day option to purchase
To follow my postings on ihub use this link : Ihub person mark
Feedback is allways appreciated, as are other (annotated) picks